

# Josep Tabernero Caturla

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3590611/josep-tabernero-caturla-publications-by-citations.pdf>  
**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

701 papers	64,051 citations	107 h-index	243 g-index
806 ext. papers	76,252 ext. citations	7.7 avg, IF	7.36 L-index

#	Paper	IF	Citations
701	Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 1691-703	59.2	3788
700	Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. <i>New England Journal of Medicine</i> , <b>2004</b> , 350, 2343-51	59.2	2728
699	The landscape of somatic copy-number alteration across human cancers. <i>Nature</i> , <b>2010</b> , 463, 899-905	50.4	2590
698	The consensus molecular subtypes of colorectal cancer. <i>Nature Medicine</i> , <b>2015</b> , 21, 1350-6	50.5	2332
697	Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , <b>2013</b> , 381, 303-12	40	1783
696	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2016</b> , 27, 1386-422	10.3	1683
695	Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. <i>Lancet Oncology, The</i> , <b>2010</b> , 11, 753-62	21.7	1653
694	Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 1023-34	59.2	1645
693	Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 3109-16	2.2	1568
692	Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , <b>2014</b> , 383, 31-39	40	1475
691	Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 4697-705	2.2	1405
690	Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 726-36	59.2	1172
689	Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. <i>Genome Research</i> , <b>2012</b> , 22, 292-8	9.7	1165
688	Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3499-506	2.2	1000
687	ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. <i>Annals of Oncology</i> , <b>2012</b> , 23, 2479-2516	10.3	984
686	Randomized trial of TAS-102 for refractory metastatic colorectal cancer. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 1909-19	59.2	720
685	Development of PI3K inhibitors: lessons learned from early clinical trials. <i>Nature Reviews Clinical Oncology</i> , <b>2013</b> , 10, 143-53	19.4	607

684	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. <i>Cancer Discovery</i> , <b>2015</b> , 5, 1164-1177	24.4	581
683	Analysis of persistence and antibiotic response in colorectal cancer. <i>Science</i> , <b>2017</b> , 358, 1443-1448	33.3	578
682	Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 499-508	21.7	568
681	The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. <i>Nature Genetics</i> , <b>2009</b> , 41, 882-4	36.3	550
680	Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 1465-71	2.2	526
679	CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. <i>Nature</i> , <b>2008</b> , 455, 547-51	50.4	519
678	First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. <i>Cancer Discovery</i> , <b>2013</b> , 3, 406-17	24.4	516
677	Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 1603-10	2.2	483
676	Encorafenib, Binimetinib, and Cetuximab in V600E-Mutated Colorectal Cancer. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 1632-1643	59.2	481
675	Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. <i>Annals of Oncology</i> , <b>2017</b> , 28, 1713-1729	10.3	454
674	Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. <i>Nature Reviews Cancer</i> , <b>2017</b> , 17, 79-92	31.3	423
673	XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 2084-91	2.2	421
672	Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. <i>Nature Communications</i> , <b>2015</b> , 6, 8839	17.4	416
671	Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. <i>JAMA Oncology</i> , <b>2017</b> , 3, 194-201	13.4	409
670	Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. <i>Lancet Oncology, The</i> , <b>2012</b> , 13, 1225-33	21.7	389
669	nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107,	9.7	368
668	Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 3117-25	2.2	354
667	Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2014</b> , 25, 1346-1355	10.3	353

666	The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. <i>Oncologist</i> , <b>2012</b> , 17, 1225-39	5.7	352
665	Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4176-87	2.2	347
664	Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors. <i>Molecular Cancer Therapeutics</i> , <b>2014</b> , 13, 1021-31	6.1	324
663	The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. <i>Molecular Cancer Research</i> , <b>2007</b> , 5, 203-20	6.6	323
662	Combined BRAF, EGFR, and MEK Inhibition in Patients with -Mutant Colorectal Cancer. <i>Cancer Discovery</i> , <b>2018</b> , 8, 428-443	24.4	296
661	Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1620-7	2.2	293
660	Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 5323-33	2.2	286
659	Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. <i>Journal of Clinical Investigation</i> , <b>2010</b> , 120, 2858-66	15.9	282
658	Ecaterin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. <i>Nature Medicine</i> , <b>2012</b> , 18, 892-901	50.5	281
657	Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3401-8	2.2	273
656	Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 5225-32	2.2	273
655	ESMO-Magnitude of Clinical Benefit Scale version 1.1. <i>Annals of Oncology</i> , <b>2017</b> , 28, 2340-2366	10.3	266
654	Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. <i>Annals of Oncology</i> , <b>2018</b> , 29, 44-70	10.3	260
653	Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. <i>Annals of Oncology</i> , <b>2014</b> , 25, 1729-1735	10.3	258
652	Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 6487-501	12.9	257
651	Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs. <i>Oncotarget</i> , <b>2010</b> , 1, 530-543	3.3	255
650	Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. <i>Lancet Oncology</i> , <b>2016</b> , 17, 1386-1395	21.7	251
649	Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3353-60	2.2	251

648	Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 3399-406	2.2	250
647	Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. <i>Annals of Oncology</i> , <b>2014</b> , 25, 552-563	10.3	242
646	Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. <i>Nature Genetics</i> , <b>2011</b> , 43, 964-968	36.3	242
645	Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 937-48	21.7	240
644	Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. <i>International Journal of Cancer</i> , <b>2014</b> , 134, 552-62	7.5	232
643	Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 1664-1670	2.2	219
642	A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 730-8	12.9	215
641	Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1787-96	2.2	213
640	Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 1437-1448	21.7	210
639	Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. <i>Nature Medicine</i> , <b>2019</b> , 25, 751-758	50.5	205
638	Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations. <i>Genome Medicine</i> , <b>2018</b> , 10, 25	14.4	205
637	Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. <i>Cancer Research</i> , <b>2012</b> , 72, 4383-93	10.1	204
636	Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. <i>European Journal of Cancer</i> , <b>2007</b> , 43, 2037-45	7.5	203
635	Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, 849-861	21.7	201
634	Caring for patients with cancer in the COVID-19 era. <i>Nature Medicine</i> , <b>2020</b> , 26, 665-671	50.5	201
633	Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 102-9	2.2	196
632	Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2020</b> , 6, 1571-1580	13.4	196
631	Potential regional differences for the tolerability profiles of fluoropyrimidines. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 2118-23	2.2	194

630	Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 1372-1384	21.7	193
629	Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 862-737	21.7	190
628	Phosphatidylinositol 3-Kinase $\gamma$ -Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1291-1299	2.2	190
627	Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 850-858	2.2	184
626	Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 3307-17	12.9	176
625	Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. <i>Oncologist</i> , <b>2013</b> , 18, 1004-12	5.7	176
624	Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 320-31	7.5	171
623	First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. <i>Oncologist</i> , <b>2012</b> , 17, 15-25	5.7	170
622	Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3733-40	2.2	159
621	Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 6296-304	12.9	155
620	Circulating tumour cells and cell-free DNA as tools for managing breast cancer. <i>Nature Reviews Clinical Oncology</i> , <b>2013</b> , 10, 377-89	19.4	146
619	Pragmatic issues in biomarker evaluation for targeted therapies in cancer. <i>Nature Reviews Clinical Oncology</i> , <b>2015</b> , 12, 197-212	19.4	139
618	Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,	9.7	138
617	Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 2603-12	12.9	137
616	Unmet needs and challenges in gastric cancer: the way forward. <i>Cancer Treatment Reviews</i> , <b>2014</b> , 40, 692-700	14.4	135
615	BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives. <i>Annals of Oncology</i> , <b>2017</b> , 28, 2648-2657	10.3	133
614	Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. <i>Annals of Oncology</i> , <b>2014</b> , 25, 2244-2251	10.3	133
613	A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic -Mutant Colorectal Cancer. <i>Cancer Discovery</i> , <b>2017</b> , 7, 610-619	24.4	132



612	Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106,	9.7	132
611	Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies. <i>Annals of Oncology</i> , <b>2017</b> , 28, 1862-1868	10.3	126
610	A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. <i>Annals of Oncology</i> , <b>2004</b> , 15, 1358-65	10.3	124
609	Status of PI3K inhibition and biomarker development in cancer therapeutics. <i>Annals of Oncology</i> , <b>2010</b> , 21, 683-691	10.3	121
608	Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , <b>2007</b> , 14, 221-32	5.7	121
607	Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 4764-74	12.9	119
606	Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 4309-16	2.2	118
605	Pushing the envelope in the mTOR pathway: the second generation of inhibitors. <i>Molecular Cancer Therapeutics</i> , <b>2011</b> , 10, 395-403	6.1	117
604	Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 794-806	12.9	116
603	Tankyrase Inhibition Blocks Wnt/ECatenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 644-56	12.9	114
602	Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1460-1469	2.2	114
601	Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. <i>Annals of Oncology</i> , <b>2012</b> , 23, 2399-2408	10.3	112
600	A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 2192-204	12.9	111
599	Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. <i>British Journal of Cancer</i> , <b>2018</b> , 119, 1208-1214	8.7	111
598	Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 4888-4897	12.9	110
597	Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2017</b> , 28, 1294-1301	10.3	107
596	Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study. <i>Targeted Oncology</i> , <b>2015</b> , 10, 111-23	5	107
595	A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction. <i>Gut</i> , <b>2013</b> , 62, 540-9	19.2	107

594	Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. <i>Annals of Oncology</i> , <b>2012</b> , 23, 897-902	10.3	107
593	Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 3224-9	2.2	107
592	A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors. <i>Cancer Discovery</i> , <b>2017</b> , 7, 102-113	24.4	105
591	Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges. <i>Nature Reviews Clinical Oncology</i> , <b>2017</b> , 14, 562-576	19.4	102
590	A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 6304-12	12.9	102
589	SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 4811-8	12.9	101
588	Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results. <i>Nephrology Dialysis Transplantation</i> , <b>2005</b> , 20, 968-73	4.3	101
587	Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. <i>Annals of Oncology</i> , <b>2019</b> , 30, 19-33	10.3	101
586	Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. <i>Oncologist</i> , <b>2015</b> , 20, 143-50	5.7	99
585	Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1181-9	2.2	99
584	Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment. <i>Cancer Treatment Reviews</i> , <b>2009</b> , 35, 354-63	14.4	99
583	Global cancer control: responding to the growing burden, rising costs and inequalities in access. <i>ESMO Open</i> , <b>2018</b> , 3, e000285	6	98
582	Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs. <i>Oncologist</i> , <b>2011</b> , 16, 1729-40	5.7	96
581	Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients. <i>Cancer Discovery</i> , <b>2020</b> ,	24.4	96
580	The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2005</b> , 3, 599-606	1.2	94
579	3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. <i>Lancet Oncology</i> , <b>2018</b> , 19, 562-578	21.7	93
578	mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. <i>Nature</i> , <b>2017</b> , 547, 109-113	50.4	92
577	Genomic medicine frontier in human solid tumors: prospects and challenges. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1874-84	2.2	90



576	Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT). <i>Annals of Oncology</i> , <b>2018</b> , 29, 2163-2174	10.3	88
575	Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial. <i>JAMA Oncology</i> , <b>2016</b> , 2, 643-653	13.4	87
574	Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors. <i>Annals of Oncology</i> , <b>2002</b> , 13, 558-65	10.3	87
573	A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. <i>Annals of Oncology</i> , <b>2013</b> , 24, 1567-73	10.3	86
572	Sorafenib in metastatic thyroid cancer. <i>Endocrine-Related Cancer</i> , <b>2012</b> , 19, 209-16	5.7	86
571	RHOA inactivation enhances Wnt signalling and promotes colorectal cancer. <i>Nature Communications</i> , <b>2014</b> , 5, 5458	17.4	85
570	The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. <i>Annals of Oncology</i> , <b>2009</b> , 20 Suppl 7, vii1-vii6	10.3	84
569	Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 4240-50	12.9	83
568	EGFR and KRAS in colorectal cancer. <i>Advances in Clinical Chemistry</i> , <b>2010</b> , 51, 71-119	5.8	83
567	Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. <i>Annals of Oncology</i> , <b>2015</b> , 26, 149-156	10.3	81
566	Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 4876-83	12.9	81
565	Current issues in adjuvant treatment of stage II colon cancer. <i>Annals of Surgical Oncology</i> , <b>2006</b> , 13, 887-98	3.8	81
564	Genomic classifier ColoPrint predicts recurrence in stage II colorectal cancer patients more accurately than clinical factors. <i>Oncologist</i> , <b>2015</b> , 20, 127-33	5.7	79
563	Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. <i>ESMO Open</i> , <b>2016</b> , 1, e000142	6	79
562	Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: a Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study. <i>Annals of Oncology</i> , <b>1998</b> , 9, 727-31	10.3	78
561	A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect. <i>Nature Communications</i> , <b>2014</b> , 5, 3608	17.4	77
560	First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 1888-95	12.9	76
559	Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 2445-56	12.9	76

558	Molecular Diagnosis of Diffuse Gliomas through Sequencing of Cell-Free Circulating Tumor DNA from Cerebrospinal Fluid. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 2812-2819	12.9	74
557	A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2013</b> , 24, 1777-1785	10.3	74
556	HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2558-2567	2.2	73
555	Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics. <i>Molecular Cancer Therapeutics</i> , <b>2010</b> , 9, 2844-2852	6.1	73
554	The expanding role of immunotherapy. <i>Cancer Treatment Reviews</i> , <b>2017</b> , 54, 74-86	14.4	72
553	Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. <i>Annals of Oncology</i> , <b>2014</b> , 25, 2378-2385	10.3	72
552	Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 3783-90	2.2	70
551	Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. <i>PLoS Genetics</i> , <b>2010</b> , 6, e1001204	6	70
550	Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. <i>Oncologist</i> , <b>2012</b> , 17, 947-55	5.7	70
549	Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. <i>British Journal of Cancer</i> , <b>2008</b> , 99, 1607-12	8.7	70
548	Molecular dissection of microsatellite instable colorectal cancer. <i>Cancer Discovery</i> , <b>2013</b> , 3, 502-11	24.4	68
547	A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy. <i>Nature</i> , <b>2018</b> , 562, 434-438	50.4	68
546	Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey. <i>Annals of Oncology</i> , <b>2017</b> , 28, 1590-1596	10.3	67
545	Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 336-349	2.2	66
544	Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. <i>Annals of Oncology</i> , <b>2015</b> , 26, 132-140	10.3	66
543	Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials. <i>Molecular Cancer Therapeutics</i> , <b>2012</b> , 11, 2062-71	6.1	66
542	A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring Gene Alterations. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 2699-2707	12.9	66
541	Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer. <i>Cancer Discovery</i> , <b>2015</b> , 5, 598-609	24.4	65

540	METGastric: A phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4012-4012	2.2	65
539	Strategies to design clinical studies to identify predictive biomarkers in cancer research. <i>Cancer Treatment Reviews</i> , <b>2017</b> , 53, 79-97	14.4	64
538	LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8 T cell tumor-infiltration impairing anti-PD1 therapy. <i>Nature Communications</i> , <b>2019</b> , 10, 2416	17.4	64
537	Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors. <i>Seminars in Oncology</i> , <b>2015</b> , 42, 801-19	5.5	64
536	Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials. <i>JAMA Oncology</i> , <b>2018</b> , 4, 379-383	13.4	64
535	Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer. <i>British Journal of Cancer</i> , <b>2017</b> , 117, 1478-1485	8.7	64
534	Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab. <i>Annals of Oncology</i> , <b>2017</b> , 28, 2932-2942	10.3	63
533	Enhancing global access to cancer medicines. <i>Ca-A Cancer Journal for Clinicians</i> , <b>2020</b> , 70, 105-124	220.7	63
532	Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer. <i>Cancer Research</i> , <b>2016</b> , 76, 4504-15	10.1	63
531	Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 6976-86	12.9	63
530	A personalized preclinical model to evaluate the metastatic potential of patient-derived colon cancer initiating cells. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 6787-801	12.9	63
529	CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. <i>Annals of Oncology</i> , <b>2016</b> , 27, 654-60	10.3	62
528	Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer. <i>Molecular Oncology</i> , <b>2012</b> , 6, 15-26	7.9	62
527	Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. <i>Annals of Oncology</i> , <b>2010</b> , 21, 1537-1545	10.3	62
526	First-Line Treatment of Metastatic Colorectal Cancer: Interpreting FIRE-3, PEAK, and CALGB/SWOG 80405. <i>Current Treatment Options in Oncology</i> , <b>2015</b> , 16, 52	5.4	61
525	Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study. <i>Annals of Oncology</i> , <b>2018</b> , 29, 602-609	10.3	61
524	Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 2541-50	12.9	61
523	Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration?. <i>Oncologist</i> , <b>2008</b> , 13, 113-9	5.7	60

522	Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 273-284	2.2	60
521	Constitutive HER2 signaling promotes breast cancer metastasis through cellular senescence. <i>Cancer Research</i> , <b>2013</b> , 73, 450-8	10.1	59
520	Novel targeted therapies in the treatment of gastric and esophageal cancer. <i>Annals of Oncology</i> , <b>2005</b> , 16, 1740-8	10.3	59
519	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. <i>ESMO Open</i> , <b>2016</b> , 1, e000097	6	59
518	KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. <i>Future Oncology</i> , <b>2019</b> , 15, 943-952	3.6	59
517	Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106, djt322	9.7	58
516	Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2008</b> , 67, 255-62	7	58
515	New clinical trial designs in the era of precision medicine. <i>Molecular Oncology</i> , <b>2019</b> , 13, 549-557	7.9	57
514	Abstract CT326: Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors <b>2014</b> ,		57
513	Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. <i>Oncologist</i> , <b>2017</b> , 22, 1049-1055	5.7	56
512	A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107, djv258	9.7	55
511	Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 996-1004	2.2	55
510	Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2018</b> , 4, e175245	13.4	54
509	First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 2205-14	12.9	54
508	Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 1231-42	7.5	53
507	Molecular prescreening to select patient population in early clinical trials. <i>Nature Reviews Clinical Oncology</i> , <b>2012</b> , 9, 359-66	19.4	52
506	Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer. <i>British Journal of Cancer</i> , <b>2016</b> , 115, 188-94	8.7	52
505	A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3K $\alpha$ Isoform Inhibitor, in Patients with Advanced Solid Malignancies. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 5015-5023	12.9	51

504	Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review. <i>Annals of Oncology</i> , <b>2017</b> , 28, 2943-2949	10.3	51
503	Cardiotoxicity. <i>Annals of Oncology</i> , <b>2010</b> , 21 Suppl 7, vii173-9	10.3	51
502	Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFM CRC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3544-3544	2.2	51
501	Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer--an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009. <i>Annals of Oncology</i> , <b>2010</b> , 21, 1579-1584	10.3	50
500	Brush border myosin Ia has tumor suppressor activity in the intestine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 1530-5	11.5	50
499	TGF-beta signalling-related markers in cancer patients with bone metastasis. <i>Biomarkers</i> , <b>2008</b> , 13, 217-366		50
498	A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 6313-21	12.9	49
497	The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007. <i>Annals of Oncology</i> , <b>2008</b> , 19 Suppl 6, vi1-8	10.3	49
496	The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 3260-7	12.9	48
495	Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. <i>Annals of Oncology</i> , <b>2019</b> , 30, 34-43	10.3	48
494	Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 3987-95	12.9	47
493	Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 1116-23	12.9	47
492	PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer. <i>Annals of Oncology</i> , <b>2016</b> , 27, 1557-65	10.3	47
491	A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer. <i>Targeted Oncology</i> , <b>2017</b> , 12, 775-785	5	46
490	Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2018</b> , 29, 119-126	10.3	46
489	An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer. <i>Oncologist</i> , <b>2014</b> , 19, 350-1	5.7	46
488	Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials). <i>European Journal of Cancer</i> , <b>2014</b> , 50, 2983-93	7.5	45
487	Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy. <i>Therapeutic Advances in Medical Oncology</i> , <b>2016</b> , 8, 230-42	5.4	45



486	TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106,	9.7	44
485	BRAF as a target for cancer therapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , <b>2011</b> , 11, 285-95	2.2	44
484	Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. <i>British Journal of Cancer</i> , <b>2016</b> , 115, 974-982	8.7	44
483	Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter. <i>Oncogene</i> , <b>2016</b> , 35, 6403-6415	9.2	43
482	Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2015</b> , e149-56	7.1	43
481	Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy. <i>Oncology</i> , <b>2004</b> , 66, 388-94	3.6	43
480	Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients. <i>Acta Oncologica</i> , <b>1998</b> , 37, 187-91	3.2	43
479	Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. <i>JAMA Oncology</i> , <b>2021</b> , 7, 895-902	13.4	43
478	First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. <i>Future Oncology</i> , <b>2021</b> , 17, 491-501	3.6	43
477	Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 2462-70	12.9	42
476	Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity. <i>Scientific Reports</i> , <b>2013</b> , 3, 3544	4.9	42
475	Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study. <i>Critical Reviews in Oncology/Hematology</i> , <b>2009</b> , 70, 134-44	7	42
474	TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence. <i>Journal of Clinical Investigation</i> , <b>2018</b> , 128, 3887-3905	15.9	41
473	Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression. <i>Annals of Oncology</i> , <b>2016</b> , 27, 2082-2090	10.3	40
472	Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer. <i>British Journal of Cancer</i> , <b>2018</b> , 119, 1464-1470	8.7	40
471	p95HER2-T cell bispecific antibody for breast cancer treatment. <i>Science Translational Medicine</i> , <b>2018</b> , 10,	17.5	40
470	A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2015</b> , 75, 1065-73	3.5	38
469	Overexpression of Yes Associated Protein 1, an Independent Prognostic Marker in Patients With Pancreatic Ductal Adenocarcinoma, Correlated With Liver Metastasis and Poor Prognosis. <i>Pancreas</i> , <b>2017</b> , 46, 913-920	2.6	38



468	Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status. <i>JAMA Oncology</i> , <b>2018</b> , 4, e173695	13.4	37
467	TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2019</b> , 83, 975-991	3.5	36
466	Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase. <i>Cancer Research</i> , <b>2011</b> , 71, 675-85	10.1	36
465	The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer.. <i>Nature</i> , <b>2021</b> , 600, 727-730	50.4	36
464	Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 1846-1855	12.9	35
463	Improving outcomes in colorectal cancer: where do we go from here?. <i>European Journal of Cancer</i> , <b>2013</b> , 49, 2476-85	7.5	34
462	Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, LBA148-LBA148	2.2	34
461	Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFM) metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 103-103	2.2	34
460	Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. <i>Targeted Oncology</i> , <b>2016</b> , 11, 383-400	5	33
459	Prognostic and predictive roles for circulating biomarkers in gastrointestinal cancer. <i>Future Oncology</i> , <b>2011</b> , 7, 1385-97	3.6	33
458	Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3511-3511	2.2	33
457	Aurora kinase family: a new target for anticancer drug. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , <b>2008</b> , 3, 114-22	2.6	33
456	Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 942-9	7.5	32
455	Application of monoclonal antibodies as cancer therapy in solid tumors. <i>Current Clinical Pharmacology</i> , <b>2012</b> , 7, 137-45	2.5	32
454	Oxaliplatin-based chemotherapy in the management of colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2008</b> , 8, 1223-36	3.5	32
453	Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 4013-4013	2.2	32
452	Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients. <i>Annals of Oncology</i> , <b>2017</b> , 28, 824-830	10.3	31
451	Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies. <i>Clinical Colorectal Cancer</i> , <b>2018</b> , 17, 170-178.e3	3.8	31

450	Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints. <i>Targeted Oncology</i> , <b>2016</b> , 11, 469-73		31
449	Molecular predictors of response to chemotherapy in colorectal cancer. <i>Cancer Journal (Sudbury, Mass )</i> , <b>2011</b> , 17, 114-26	2.2	31
448	Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 2375-82	12.9	31
447	Phase II randomized study of Plitidepsin (Aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma. <i>Marine Drugs</i> , <b>2009</b> , 7, 57-70	6	31
446	Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3515-3515	2.2	31
445	Early evolutionary divergence between papillary and anaplastic thyroid cancers. <i>Annals of Oncology</i> , <b>2018</b> , 29, 1454-1460	10.3	30
444	Epigenetic Homogeneity Within Colorectal Tumors Predicts Shorter Relapse-Free and Overall Survival Times for Patients With Locoregional Cancer. <i>Gastroenterology</i> , <b>2016</b> , 151, 961-972	13.3	30
443	Biomarker-driven patient selection for early clinical trials. <i>Current Opinion in Oncology</i> , <b>2013</b> , 25, 305-12	4.2	30
442	Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2009</b> , 75, 1430-6	4	30
441	Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology. <i>ESMO Open</i> , <b>2019</b> , 4, e000460	6	29
440	Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas. <i>Annals of Oncology</i> , <b>2016</b> , 27, 648-53	10.3	29
439	A pharmacodynamic/pharmacokinetic study of ficlatuzumab in patients with advanced solid tumors and liver metastases. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 2793-804	12.9	29
438	What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer?. <i>Critical Reviews in Oncology/Hematology</i> , <b>2014</b> , 92, 83-106	7	29
437	BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: the Spanish Germ-Cell Cancer Group experience (GG). <i>Annals of Oncology</i> , <b>1999</b> , 10, 289-93	10.3	29
436	Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study. <i>Annals of Oncology</i> , <b>2019</b> , 30, 124-131	10.3	29
435	Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients. <i>Oncologist</i> , <b>2016</b> , 21, 292-300	5.7	28
434	Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. <i>European Journal of Cancer</i> , <b>2017</b> , 82, 16-24	7.5	28
433	Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer. <i>British Journal of Cancer</i> , <b>2013</b> , 109, 1735-43	8.7	28

432	Mediastinal non-seminomatous germ cell tumours (MNSGCT) treated with cisplatin-based combination chemotherapy. <i>Annals of Oncology</i> , <b>1997</b> , 8, 555-9	10.3	28
431	Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3001-3001	2.2	28
430	MAESTRO: A randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients (pts) with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4007-4007	2.2	28
429	BEACON CRC study safety lead-in (SLI) in patients with BRAFV600E metastatic colorectal cancer (mCRC): Efficacy and tumor markers.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 627-627	2.2	28
428	Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies. <i>PLoS ONE</i> , <b>2015</b> , 10, e0129876	3.7	28
427	Extracellular HMGA1 Promotes Tumor Invasion and Metastasis in Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 6367-6382	12.9	27
426	Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2017</b> , 16, 2215-2222	6.1	27
425	Precision oncology in metastatic colorectal cancer - from biology to medicine. <i>Nature Reviews Clinical Oncology</i> , <b>2021</b> , 18, 506-525	19.4	27
424	Current and advancing treatments for metastatic colorectal cancer. <i>Expert Opinion on Biological Therapy</i> , <b>2016</b> , 16, 93-110	5.4	26
423	HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab. <i>Annals of Oncology</i> , <b>2013</b> , 24, 3123-8	10.3	26
422	Targeted therapy in advanced colon cancer: the role of new therapies. <i>Annals of Oncology</i> , <b>2004</b> , 15 Suppl 4, iv55-62	10.3	26
421	A phase II, double-blind study of galunisertib+gemcitabine (GG) vs gemcitabine+placebo (GP) in patients (pts) with unresectable pancreatic cancer (PC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4019-4019	3.2	26
420	Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line Wild-Type Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 2276-2284	12.9	25
419	The European Cancer Patient's Bill of Rights, update and implementation 2016. <i>ESMO Open</i> , <b>2016</b> , 1, e000127	6	25
418	Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer. <i>British Journal of Cancer</i> , <b>2015</b> , 112, 1874-81	8.7	25
417	Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphoma. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 1763-70	1.9	25
416	A shining light in the darkness for the treatment of pancreatic neuroendocrine tumors. <i>Cancer Discovery</i> , <b>2011</b> , 1, 213-21	24.4	25
415	New drugs and new approaches in metastatic bladder cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2003</b> , 47, 195-206	7	25

414	Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 2521-33	2.2	25
413	Molecular Subtypes and the Evolution of Treatment Decisions in Metastatic Colorectal Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2018</b> , 38, 231-238	7.1	25
412	Optimal design of trials to demonstrate the utility of genomically-guided therapy: Putting Precision Cancer Medicine to the test. <i>Molecular Oncology</i> , <b>2015</b> , 9, 940-50	7.9	24
411	Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 496-505	7.5	24
410	Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2013</b> , 72, 75-83	3.5	24
409	The evolution of our molecular understanding of colorectal cancer: what we are doing now, what the future holds, and how tumor profiling is just the beginning. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2014</b> , 91-9	7.1	24
408	A catalyst for change: the European cancer Patient's Bill of Rights. <i>Oncologist</i> , <b>2014</b> , 19, 217-24	5.7	24
407	Immunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patients. <i>PLoS ONE</i> , <b>2013</b> , 8, e80437	3.7	24
406	A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5-fluorouracil (CNF) versus cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>1995</b> , 34, 15-24	4.4	24
405	Changing the paradigm in conducting randomized clinical studies in advanced pancreatic cancer: an opportunity for better clinical development. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 5487-91	2.2	23
404	Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 215-23	12.9	23
403	Novel targets in gastric and esophageal cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2006</b> , 59, 128-38	3.8	23
402	Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score $\geq 10$ . <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 1923-1931	12.9	23
401	Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?. <i>Annals of Oncology</i> , <b>2017</b> , 28, 1207-1216	10.3	22
400	Cancer Core Europe: A translational research infrastructure for a European mission on cancer. <i>Molecular Oncology</i> , <b>2019</b> , 13, 521-527	7.9	22
399	Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer. <i>British Journal of Cancer</i> , <b>2016</b> , 114, 372-80	8.7	22
398	Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab. <i>Molecular Cancer</i> , <b>2014</b> , 13, 141	42.1	22
397	Impact of glucose-lowering agents on the risk of cancer in type 2 diabetic patients. The Barcelona case-control study. <i>PLoS ONE</i> , <b>2013</b> , 8, e79968	3.7	22

396	Development of molecular biomarkers in individualized treatment of colorectal cancer. <i>Clinical Colorectal Cancer</i> , <b>2011</b> , 10, 279-89	3.8	22
395	Incidence of contralateral germ cell testicular tumors in South Europe: report of the experience at 2 Spanish university hospitals and review of the literature. <i>Journal of Urology</i> , <b>2004</b> , 171, 164-7	2.5	22
394	Abstract LB-122: A phase I dose escalation study of NVP-BGJ398, a selective pan FGFR inhibitor in genetically preselected advanced solid tumors <b>2012</b> ,		22
393	First-in-human phase 1/2 study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3: Final phase 1 data and preliminary activity in HER2+ metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2522-2522	2.2	22
392	BMS-986205, an indoleamine 2, 3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (nivo): Updated safety across all tumor cohorts and efficacy in advanced bladder cancer (advBC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 358-358	2.2	22
391	Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4001-4001	2.2	22
390	Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study). <i>ESMO Open</i> , <b>2016</b> , 1, e000111	6	22
389	Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial. <i>European Journal of Cancer</i> , <b>2017</b> , 78, 61-69	7.5	21
388	Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab. <i>Targeted Oncology</i> , <b>2015</b> , 10, 65-76	5	21
387	Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancer. <i>Molecular Oncology</i> , <b>2019</b> , 13, 1827-1835	7.9	21
386	Circulating pEGFR is a candidate response biomarker of cetuximab therapy in colorectal cancer. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 6346-56	12.9	21
385	SPROUTY2 is a Eatenin and FOXO3a target gene indicative of poor prognosis in colon cancer. <i>Oncogene</i> , <b>2014</b> , 33, 1975-85	9.2	21
384	Improving the Armamentarium of PI3K Inhibitors with Isoform-Selective Agents: A New Light in the Darkness. <i>Cancer Discovery</i> , <b>2017</b> , 7, 666-669	24.4	21
383	Treatment recommendations for metastatic colorectal cancer. <i>Clinical and Translational Oncology</i> , <b>2011</b> , 13, 162-78	3.6	21
382	Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights. <i>Molecular Oncology</i> , <b>2017</b> , 11, 1263-1272	7.9	20
381	Cancer Core Europe: a consortium to address the cancer care-cancer research continuum challenge. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 2745-6	7.5	20
380	Cancer: A precision approach to tumour treatment. <i>Nature</i> , <b>2017</b> , 548, 40-41	50.4	20
379	Intrinsic cancer subtypes--next steps into personalized medicine. <i>Cellular Oncology (Dordrecht)</i> , <b>2015</b> , 38, 3-16	7.2	20



378	A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2012</b> , 23, 119-127	10.3	20
377	KEYNOTE-062: Phase III study of pembrolizumab (MK-3475) alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS185-TPS185	2.2	20
376	Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. <i>Lancet Oncology</i> , <b>2021</b> , 22, 1669-1680	21.7	20
375	Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal. <i>Nature Medicine</i> , <b>2020</b> , 26, 992-994	50.5	19
374	-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 2466-2476	12.9	19
373	Recent developments in anti-cancer agents targeting PI3K, Akt and mTORC1/2. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , <b>2011</b> , 6, 210-36	2.6	19
372	Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial. <i>Annals of Oncology</i> , <b>2015</b> , 26, 1936-1941	10.3	18
371	Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECURSE trial. <i>Clinical and Translational Oncology</i> , <b>2017</b> , 19, 227-235	3.6	18
370	Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer. <i>PLoS ONE</i> , <b>2013</b> , 8, e62264	3.7	18
369	Toward efficient trials in colorectal cancer: the ARCAD Clinical Trials Program. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 527-30	2.2	18
368	Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2501-2501	2.2	18
367	Impact of Prior Bevacizumab Treatment on VEGF-A and PlGF Levels and Outcome Following Second-Line Aflibercept Treatment: Biomarker Analysis of the VELOUR Trial. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 717-725	12.9	18
366	Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment. <i>Nature Communications</i> , <b>2021</b> , 12, 1503	17.4	18
365	-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial. <i>OncoTargets and Therapy</i> , <b>2017</b> , 10, 591-596	4.4	17
364	Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factors. <i>Critical Reviews in Oncology/Hematology</i> , <b>2013</b> , 85, 121-35	7	17
363	VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2512-2512	2.2	17
362	Evofofosamide (TH-302) in combination with gemcitabine in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma: Primary analysis of the randomized, double-blind phase III MAESTRO study.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 193-193	2.2	17
361	Pharmacokinetic/Pharmacodynamic Modeling for Drug Development in Oncology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2017</b> , 37, 210-215	7.1	17



360	CanStem111P trial: a Phase III study of napabucasin plus nab-paclitaxel with gemcitabine. <i>Future Oncology</i> , <b>2019</b> , 15, 1295-1302	3.6	17
359	Rationale and Design for the LUME-Colon 1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Nintedanib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Colorectal Cancer Refractory to Standard Treatment. <i>Clinical Colorectal Cancer</i> , <b>2018</b> , 15, 91-94.e1	3.8	16
358	Methodological aspects of the molecular and histological study of prostate cancer: focus on PTEN. <i>Methods</i> , <b>2015</b> , 77-78, 25-30	4.6	16
357	Improving survival and local control in rectal cancer in Catalonia (Spain) in the context of centralisation: A full cycle audit assessment. <i>European Journal of Surgical Oncology</i> , <b>2016</b> , 42, 1873-1880	3.6	16
356	Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial. <i>ESMO Open</i> , <b>2017</b> , 2, e000261	6	16
355	Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial. <i>British Journal of Cancer</i> , <b>2011</b> , 105, 1646-53	8.7	16
354	First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours. <i>British Journal of Cancer</i> , <b>2012</b> , 106, 1379-85	8.7	16
353	Effect of adding oxaliplatin to adjuvant 5-fluorouracil/leucovorin (5FU/LV) in patients with defective mismatch repair (dMMR) colon cancer stage II and III included in the MOSIAC study.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3524-3524	2.2	16
352	Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , <b>2020</b> , 12, 1758835920936089	5.4	16
351	A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS. <i>Oncologist</i> , <b>2017</b> , 22, 1024-e89	5.7	15
350	Pharmacokinetic/Pharmacodynamic Modeling for Drug Development in Oncology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2017</b> , 37, 210-215	7.1	15
349	Cyclin E amplification/overexpression is associated with poor prognosis in gastric cancer. <i>Annals of Oncology</i> , <b>2015</b> , 26, 438-9	10.3	15
348	Panitumumab: a summary of clinical development in colorectal cancer and future directions. <i>Future Oncology</i> , <b>2012</b> , 8, 373-89	3.6	15
347	Monoclonal antibodies in the treatment of advanced colorectal cancer. <i>European Journal of Surgical Oncology</i> , <b>2007</b> , 33 Suppl 2, S24-34	3.6	15
346	Alpha-fetoprotein-concanavalin A binding as a marker to discriminate between germ cell tumours and liver diseases. <i>European Journal of Cancer</i> , <b>1995</b> , 31A, 2239-42	7.5	15
345	Abstract CT325: First in human study of JNJ-42756493, a potent pan fibroblast growth factor receptor (FGFR) inhibitor in patients with advanced solid tumors <b>2014</b> ,		15
344	Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3502-3502	2.2	15
343	Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic CRC, gastric cancer (GC), SCCHN, or other tumors.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3622-3622	2.2	15

342	Molecular subtypes and outcomes in regorafenib-treated patients with metastatic colorectal cancer (mCRC) enrolled in the CORRECT trial.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3558-3558	2.2	15
341	Exposure-response (E-R) relationship of ramucirumab (RAM) from two global, randomized, double-blind, phase 3 studies of patients (Pts) with advanced second-line gastric cancer.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 121-121	2.2	15
340	Towards a cancer mission in Horizon Europe: recommendations. <i>Molecular Oncology</i> , <b>2020</b> , 14, 1589-1615	9	15
339	Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy. <i>Annals of Oncology</i> , <b>2019</b> , 30, 439-446	10.3	14
338	Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2018</b> , 33, 814-824	4	14
337	Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 4745-4753	12.9	14
336	Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules. <i>ESMO Open</i> , <b>2017</b> , 2, e000216	6	14
335	Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development. <i>Cancer Treatment Reviews</i> , <b>2015</b> , 41, 129-35	14.4	14
334	Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysis. <i>Medical Oncology</i> , <b>2011</b> , 28 Suppl 1, S253-8	3.7	14
333	A phase Ib, open-label, multicenter, dose-escalation study of the oral pan-PI3K inhibitor BKM120 in combination with the oral MEK1/2 inhibitor GSK1120212 in patients (pts) with selected advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3003-3003	2.2	14
332	Time course of regorafenib-associated adverse events in the phase III CORRECT study.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 467-467	2.2	14
331	Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the $\pi$ -specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3514-3514	2.2	14
330	Pancreatic cancer heterogeneity and response to Mek inhibition. <i>Oncogene</i> , <b>2017</b> , 36, 5639-5647	9.2	14
329	A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. <i>Radiology</i> , <b>2021</b> , 299, 109-119	20.5	14
328	Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study. <i>European Journal of Cancer</i> , <b>2021</b> , 150, 190-202	7.5	14
327	Spectrum of Gene Mutations in Colorectal Cancer: Implications for Treatment. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2016</b> , 22, 149-55	2.2	14
326	Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring Mutations: A Cohort of the Histology-Independent VE-BASKET Study. <i>JCO Precision Oncology</i> , <b>2018</b> , 2,	3.6	14
325	Short- and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Intensified Neoadjuvant Strategy in the Randomized Phase 2 EXPERT-C Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2015</b> , 93, 303-12	4	13

324	MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 5499-5510	12.9	13
323	Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data set. <i>ESMO Open</i> , <b>2018</b> , 3, e000347	6	13
322	Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients. <i>Carcinogenesis</i> , <b>2016</b> , 37, 852-7	4.6	13
321	Quality of life during first-line FOLFOX4+panitumumab in wild-type metastatic colorectal carcinoma: results from a randomised controlled trial. <i>ESMO Open</i> , <b>2016</b> , 1, e000041	6	13
320	A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors. <i>Investigational New Drugs</i> , <b>2012</b> , 30, 299-305	4.3	13
319	Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer. <i>Clinical Colorectal Cancer</i> , <b>2008</b> , 7 Suppl 2, S52-7	3.8	13
318	Phase II study of trabectedin in pretreated patients with advanced colorectal cancer. <i>Clinical Colorectal Cancer</i> , <b>2007</b> , 6, 522-8	3.8	13
317	Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2008</b> , 62, 1075-83	3.5	13
316	KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJC): A double-blind, randomized, placebo-controlled phase 3 study.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, TPS4146-TPS4146	2.2	13
315	Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry. <i>JAMA Oncology</i> , <b>2021</b> ,	13.4	13
314	3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT. <i>Health Technology Assessment</i> , <b>2019</b> , 23, 1-88	4.4	13
313	Epigenetic Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 902-909	12.9	13
312	A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. <i>BMC Cancer</i> , <b>2017</b> , 17, 646	4.8	12
311	Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2017</b> , 80, 599-608	3.5	12
310	QTwIST analysis of the RECURSE trial of trifluridine/tipiracil in metastatic colorectal cancer. <i>ESMO Open</i> , <b>2017</b> , 2, e000284	6	12
309	Micromanaging the classification of colon cancer: the role of the microRNAome. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 7207-9	12.9	12
308	Control of carcinoid syndrome with everolimus. <i>Annals of Oncology</i> , <b>2011</b> , 22, 237-239	10.3	12
307	Using pharmacokinetic and pharmacodynamic data in early decision making regarding drug development: a phase I clinical trial evaluating tyrosine kinase inhibitor, AEE788. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 6364-72	12.9	12

306	Pre-operative chemoradiotherapy with UFT and Leucovorin in patients with advanced rectal cancer: a phase II study. <i>Radiotherapy and Oncology</i> , <b>2008</b> , 89, 263-9	5.3	12
305	Irreversible pan-ErbB tyrosine kinase inhibitor CI-1033 induces caspase-independent apoptosis in colorectal cancer DiFi cell line. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , <b>2005</b> , 10, 1175-86	5.4	12
304	Abstract C252: A phase 1, dose-escalation study of MLN0128, an investigational oral mammalian target of rapamycin complex 1/2 (mTORC1/2) catalytic inhibitor, in patients (pts) with advanced non-hematologic malignancies. <b>2013</b> ,		12
303	Abstract CT050: A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors <b>2016</b> ,		12
302	MetGastric: A randomized phase III study of onartuzumab (MetMab) in combination with mFOLFOX6 in patients with metastatic HER2-negative and MET-positive adenocarcinoma of the stomach or gastroesophageal junction.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, TPS4155-TPS4155	2.2	12
301	Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 178-178	2.2	12
300	Final results from the phase I study expansion cohort of the selective FGFR inhibitor Debio 1,347 in patients with solid tumors harboring an FGFR gene fusion.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3603-3603	2.2	12
299	Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies. <i>Molecular Cancer Therapeutics</i> , <b>2016</b> , 15, 1106-12	6.1	12
298	Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer. <i>Scientific Reports</i> , <b>2019</b> , 9, 13568	4.9	11
297	MODUL-a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2018</b> , 144, 1197-1204	4.9	11
296	Dose-response relationship in phase i clinical trials: a European Drug Development Network (EDDN) Collaboration Study. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 5663-71	12.9	11
295	The role of salvage treatment in advanced colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2009</b> , 71, 53-61	7	11
294	Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study. <i>Acta Oncologica</i> , <b>2008</b> , 47, 286-92	3.2	11
293	Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 4005-4005	2.2	11
292	Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score <b>2021</b> , 9,		11
291	ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers. <i>ESMO Open</i> , <b>2016</b> , 1, e000100	6	11
290	Brexit: a European perspective. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 558-9	21.7	11
289	First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors. <i>Investigational New Drugs</i> , <b>2019</b> , 37, 674-683	4.3	11

288	Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 2515-2522	12.9	11
287	Cancer Core Europe: A European cancer research alliance realizing a research infrastructure with critical mass and programmatic approach to cure cancer in the 21st century. <i>European Journal of Cancer</i> , <b>2018</b> , 103, 155-159	7.5	11
286	Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial. <i>British Journal of Cancer</i> , <b>2019</b> , 121, 312-317	8.7	10
285	New trends in epidermal growth factor receptor-directed monoclonal antibodies. <i>Immunotherapy</i> , <b>2009</b> , 1, 965-82	3.8	10
284	Novel targets for anticancer treatment development in colorectal cancer. <i>Clinical Colorectal Cancer</i> , <b>2006</b> , 6, 265-72	3.8	10
283	A phase II, open-label study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC): CP12-0709/NCT00862784.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 533-533	2.2	10
282	Pertuzumab (P) with trastuzumab (T) and chemotherapy (CTX) in patients (pts) with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) cancer: An international phase III study (JACOB).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, TPS4150-TPS4150	2.2	10
281	REGARD: A phase III, randomized, double-blinded trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and/or fluorouracil-based therapy.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, TPS4150-TPS4150	2.2	10
280	GAIN-(C): Efficacy and safety analysis of imgatuzumab (GA201), a novel dual-acting monoclonal antibody (mAb) designed to enhance antibody-dependent cellular cytotoxicity (ADCC), in combination with FOLFIRI compared to cetuximab plus FOLFIRI in second-line KRAS exon 2 wild type (e2WT) or with FOLFIRI alone in mutated (e2MT) metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4037-4037	2.2	10
279	Preliminary safety data from KEYNOTE-059: Pembrolizumab plus 5-fluorouracil (5-FU) and cisplatin for first-line treatment of advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4037-4037	2.2	10
278	Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Phase 3 KEYNOTE-061 study.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS183-TPS183	2.2	10
277	Debio 1347, an oral FGFR inhibitor: Results from a first-in-human, phase I dose-escalation study in patients with FGFR genomically activated advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2500-2500	2.2	10
276	How I treat gastric adenocarcinoma. <i>ESMO Open</i> , <b>2019</b> , 4, e000521	6	10
275	The role of PIGF blockade in the treatment of colorectal cancer: overcoming the pitfalls. <i>Expert Opinion on Biological Therapy</i> , <b>2020</b> , 20, 15-22	5.4	10
274	Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS. <i>Gastric Cancer</i> , <b>2020</b> , 23, 689-698	7.6	9
273	The safety of ramucirumab for the treatment of colorectal cancer. <i>Expert Opinion on Drug Safety</i> , <b>2018</b> , 17, 945-951	4.1	9
272	Evaluation of aflibercept in the treatment of metastatic colorectal cancer. <i>Expert Opinion on Biological Therapy</i> , <b>2014</b> , 14, 1493-505	5.4	9
271	Abstract CT-02: A phase I, open label, dose escalation study of oral mammalian target of rapamycin inhibitor INK128 administered by intermittent dosing regimens in patients with advanced malignancies <b>2012</b> ,		9



270	Abstract CT110: Randomized phase II study of duligotuzumab + FOLFIRI versus cetuximab + FOLFIRI in 2nd-line patients with KRAS wild-type (wt) metastatic colorectal cancer (mCRC) <b>2015</b> ,		9
269	Abstract CT068: A randomized phase II, double-blind study to evaluate the efficacy and safety of galunisertib+gemcitabine (GG) or gemcitabine+placebo (GP) in patients with unresectable pancreatic cancer (PC) <b>2016</b> ,		9
268	Effects of prior bevacizumab (B) use on outcomes from the VELOUR study: A phase III study of aflibercept (Afl) and FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin regimen.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3505-3505	2.2	9
267	Meta-analysis of anti-VEGF class adverse events from three double-blind (Db) placebo (Pbo)-controlled phase III trials with IV aflibercept (Afl).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 561-561	2.2	9
266	A phase 1 study of LJM716 in patients with esophageal squamous cell carcinoma, head and neck cancer, or HER2-overexpressing metastatic breast or gastric cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2517-2517	2.2	9
265	CEA-targeted engineered IL2: Clinical confirmation of tumor targeting and evidence of intra-tumoral immune activation.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3016-3016	2.2	9
264	AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. <i>European Journal of Cancer</i> , <b>2020</b> , 138, 1-10	7.5	9
263	SARS-CoV-2 vaccination and phase 1 cancer clinical trials. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 298-301	21.7	9
262	SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer. <i>British Journal of Cancer</i> , <b>2018</b> , 119, 1332-1338	8.7	9
261	Optimization of Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2017</b> , 16, 1999-2007	6.1	8
260	Population pharmacokinetics and exposure-overall survival analysis of the transforming growth factor- $\beta$ inhibitor galunisertib in patients with pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2019</b> , 84, 1003-1015	3.5	8
259	A phase I pharmacokinetic study of PM00104 (Zalypsis) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2013</b> , 71, 1247-54	3.5	8
258	The targeted therapy revolution in neuroendocrine tumors: in search of biomarkers for patient selection and response evaluation. <i>Cancer and Metastasis Reviews</i> , <b>2013</b> , 32, 465-77	9.6	8
257	Multigene assays to improve assessment of recurrence risk and benefit from chemotherapy in early-stage colon cancer: has the time finally arrived, or are we still stage locked?. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 3904-7	2.2	8
256	Handling side-effects of targeted therapies: safety of targeted therapies in solid tumours. <i>Annals of Oncology</i> , <b>2008</b> , 19 Suppl 7, vii146-52	10.3	8
255	Abstract 5588: A phase I, open label, dose escalation study of an oral mammalian target of rapamycin inhibitor INK128 administered once daily in patients with advanced malignancies <b>2012</b> ,		8
254	RAISE: A randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1023-1023	2.2	8
253	TAS-102 versus placebo plus best supportive care in patients with metastatic colorectal cancer refractory to standard therapies: Final survival results of the phase III RECURSE trial.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 634-634	2.2	8



252	CanStem111P trial: A phase III study of nab-paclitaxel (nab-PTX) with gemcitabine (gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS4148-TPS4148	2.2	8
251	Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO). <i>ESMO Open</i> , <b>2016</b> , 1, e000107	6	8
250	Clinical management of metastatic colorectal cancer in the era of precision medicine.. <i>Ca-A Cancer Journal for Clinicians</i> , <b>2022</b> ,	220.7	8
249	Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer: Analysis of the MOSAIC and PETACC-8 Trials. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2019</b> , 28, 1153-1161	4	7
248	A phase I study of MEHD7945A (MEHD), a first-in-class HER3/EGFR dual-action antibody, in patients (pts) with refractory/recurrent epithelial tumors: Expansion cohorts.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2568-2568	2.2	7
247	Clinical and technical validation of a genomic classifier (ColoPrint) for predicting outcome of patients with stage II colon cancer.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 384-384	2.2	7
246	A phase Ib dose escalation, safety, and tolerability study of sonidegib in combination with gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 371-371	2.2	7
245	Placental growth factor and the angiogenic environment based on analysis of baseline plasma biomarkers from the VELOUR trial.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 592-592	2.2	7
244	MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancerA randomized, double-blind, placebo-controlled, phase 3 study.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS4151-TPS4151	2.2	7
243	Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2020</b> , 6, e193531	13.4	7
242	Triple-drug chemotherapy regimens in combination with an anti-EGFR agent in metastatic colorectal cancer - prospects from phase II clinical trials. <i>Expert Opinion on Investigational Drugs</i> , <b>2019</b> , 28, 463-471	5.9	6
241	Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer. <i>Expert Opinion on Emerging Drugs</i> , <b>2016</b> , 21, 267-82	3.7	6
240	Enhancing the Biological Relevance of Secretome-Based Proteomics by Linking Tumor Cell Proliferation and Protein Secretion. <i>Journal of Proteome Research</i> , <b>2014</b> , 13, 3706-3721	5.6	6
239	PELO negatively regulates HER receptor signalling and metastasis. <i>Oncogene</i> , <b>2014</b> , 33, 1190-7	9.2	6
238	Update on novel strategies to optimize cetuximab therapy in patients with metastatic colorectal cancer. <i>Clinical Colorectal Cancer</i> , <b>2008</b> , 7, 300-8	3.8	6
237	Abstract A167: First-in-patient study of PF-05212384, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: Update on safety, efficacy, and pharmacology. <b>2011</b> ,		6
236	Molecular analysis of the randomized phase II/III study of the anti-IGF-1R antibody dalotuzumab (MK-0646) in combination with cetuximab (Cx) and irinotecan (Ir) in the treatment of chemorefractory KRAS wild-type metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3531-3531	2.2	6
235	Capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III colon cancer: Survival follow-up of study NO16968 (XELOXA).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 388-388	2.2	6

234	Overall survival (OS) analysis from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first-line metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3620-3620	2.2	6
233	Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOX+/- cetuximab: A pooled analysis of 3934 pts from the PETACC8 and N0147 trials.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3507-3507	2.2	6
232	POSEIDON trial phase 1b results: Safety and preliminary efficacy of the isoform selective PI3K inhibitor taselisib (GDC-0032) combined with tamoxifen in hormone receptor (HR) positive, HER2-negative metastatic breast cancer (MBC) patients (pts) - including response monitoring by plasma circulating tumor (ct) DNA.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2520-2520	2.2	6
231	Phase III RECURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: Geographic subgroups.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 646-646	2.2	6
230	The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, TPS4124-TPS4124	2.2	6
229	Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial. <i>Molecular Cancer Therapeutics</i> , <b>2020</b> , 19, 312-317	6.1	6
228	MOUNTAINEER:open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS153-TPS153	2.2	6
227	Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer. <i>European Journal of Cancer</i> , <b>2019</b> , 112, 12-19	7.5	5
226	Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial. <i>JAMA Network Open</i> , <b>2020</b> , 3, e2020425	10.4	5
225	TTD consensus document on the diagnosis and management of exocrine pancreatic cancer. <i>Clinical and Translational Oncology</i> , <b>2014</b> , 16, 865-78	3.6	5
224	Panitumumab - an effective long-term treatment for patients with metastatic colorectal cancer and wild-type KRAS status. <i>Cancer Treatment Reviews</i> , <b>2010</b> , 36 Suppl 1, S15-6	14.4	5
223	Integration of anti-epidermal growth factor receptor therapies with cytotoxic chemotherapy. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2010</b> , 16, 226-34	2.2	5
222	Molecular biology of testicular germ cell tumors. <i>Clinical and Translational Oncology</i> , <b>2006</b> , 8, 846-50	3.6	5
221	Guides for adjuvant treatment of colon cancer. TTD Group (Spanish Cooperative Group for Gastrointestinal Tumor Therapy). <i>Clinical and Translational Oncology</i> , <b>2006</b> , 8, 98-102	3.6	5
220	Abstract B154: A first-in-human trial of GDC-0068: A novel, oral, ATP-competitive Akt inhibitor, demonstrates robust suppression of the Akt pathway in surrogate and tumor tissues. <b>2011</b> ,		5
219	A phase Ib study of the Akt inhibitor GDC-0068 with docetaxel (D) or mFOLFOX-6 (F) in patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3021-3021	2.2	5
218	Open-label extension study of the RNAi therapeutic ALN-VSP02 in cancer patients responding to therapy.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3062-3062	2.2	5
217	Proof-of-concept study of Sym004, an anti-EGFR monoclonal antibody (mAb) mixture, in patients (pts) with anti-EGFR mab-refractory KRAS wild-type (wt) metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3551-3551	2.2	5

216	Panex: A pooled analysis of EXPERT and EXPERT-C, two trials of neoadjuvant chemotherapy (NACT) and chemoradiotherapy (CRT) in high-risk locally advanced rectal cancer (LARC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3575-3575	2.2	5
215	First-in-human, phase I, dose-escalation study of selective PI3K $\alpha$ isoform inhibitor MLN1117 in patients (pts) with advanced solid malignancies.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2501-2501	2.2	5
214	Toxicity and quality of life data from SCOT: An international phase III randomized (1:1) noninferiority trial comparing 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3514-3514	2.2	5
213	Pembrolizumab (MK-3475) plus 5-fluorouracil (5-FU) and cisplatin for first-line treatment of advanced gastric cancer: Preliminary safety data from KEYNOTE-059.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 161-161	2.2	5
212	A randomized, multicenter, double-blind, placebo-controlled study of the Bruton tyrosine kinase inhibitor, ibrutinib, versus placebo in combination with nab-paclitaxel and gemcitabine in the first-line treatment of patients with metastatic pancreatic adenocarcinoma (RESOLVE).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS183-TPS183	2.2	5
211	Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS1633-TPS1633	2.2	5
210	Phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) versus gemcitabine (Gem) alone for patients with resected pancreatic cancer (PC): Outcomes by geographic region.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4515-4515	2.2	5
209	Effect of trifluridine/tipiracil in patients treated in RECURSE by prognostic factors at baseline: an exploratory analysis. <i>ESMO Open</i> , <b>2020</b> , 5,	6	5
208	Preparing for the incoming wave of biosimilars in oncology. <i>ESMO Open</i> , <b>2018</b> , 3, e000420	6	5
207	and inhibition as treatment strategies in V600E metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , <b>2021</b> , 13, 1758835921992974	5.4	5
206	Evolving Landscape of Molecular Prescreening Strategies for Oncology Early Clinical Trials. <i>JCO Precision Oncology</i> , <b>2020</b> , 4,	3.6	4
205	Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials. <i>JCO Precision Oncology</i> , <b>2020</b> , 4,	3.6	4
204	Evaluating trifluridine + tipiracil hydrochloride in a fixed combination (TAS-102) for the treatment of colorectal cancer. <i>Expert Opinion on Pharmacotherapy</i> , <b>2018</b> , 19, 623-629	4	4
203	Prognosis and Therapeutic Implications for Emerging Colorectal Cancer Subtypes. <i>Current Colorectal Cancer Reports</i> , <b>2014</b> , 10, 55-61	1	4
202	Paracrine network: another step in the complexity of resistance to EGFR blockade?. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 6227-9	12.9	4
201	Consensus on the treatment of pancreatic cancer in Spain. <i>Clinical and Translational Oncology</i> , <b>2009</b> , 11, 290-301	3.6	4
200	New approaches and targets in advanced colorectal cancer. <i>European Journal of Cancer</i> , <b>2009</b> , 45 Suppl 1, 79-88	7.5	4
199	Biomarkers for Therapies Directed at Angiogenesis. <i>Current Colorectal Cancer Reports</i> , <b>2010</b> , 6, 133-143	1	4

198	Epidermal growth factor receptor (EGFR) inhibitors in gastrointestinal cancer. <i>Oncology Research and Treatment</i> , <b>2006</b> , 29, 99-105	2.8	4
197	CHOP chemotherapy of intermediate and high-grade non-Hodgkin's lymphoma. <i>Acta Oncologica</i> , <b>1994</b> , 33, 935-9	3.2	4
196	Validation of a genomic classifier (ColoPrint) for predicting outcome in the T3-MSS subgroup of stage II colon cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3510-3510	2.2	4
195	Final skin toxicity (ST) and patient-reported outcomes (PRO) results from PRIME: A randomized phase III study of panitumumab (pmab) plus FOLFOX4 (CT) for first-line metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 531-531	2.2	4
194	Analysis of plasma protein biomarkers from the CORRECT phase III study of regorafenib for metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3514-3514	2.2	4
193	A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, TPS4137-TPS4137	2.2	4
192	Improving access to molecularly defined clinical trials for patients with colorectal cancer: The EORTC SPECTAcOLOR platform.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 575-575	2.2	4
191	A randomized, double-blind, placebo-controlled study of ibrutinib, a Bruton tyrosine kinase inhibitor, with nab-paclitaxel and gemcitabine in the first-line treatment of patients with metastatic pancreatic adenocarcinoma (RESOLVE).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS2601-TPS2601	2.2	4
190	Pembrolizumab versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Phase 3 KEYNOTE-061 study.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS4137-TPS4137	2.2	4
189	Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials. <i>European Journal of Cancer</i> , <b>2021</b> , 144, 101-112	7.5	4
188	Shortages of inexpensive essential medicines. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, e224-e225	21.7	3
187	Nomogram for Estimating Overall Survival in Patients With Metastatic Pancreatic Cancer. <i>Pancreas</i> , <b>2020</b> , 49, 744-750	2.6	3
186	Applying the ESMO-Magnitude of Clinical Benefit Scale in real life. <i>ESMO Open</i> , <b>2016</b> , 1, e000090	6	3
185	Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial. <i>International Journal of Cancer</i> , <b>2017</b> , 140, 431-439	7.5	3
184	New approaches but the same flaws in the search for prognostic signatures. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 2019-22	12.9	3
183	Recomendaciones para la determinaci3n de mutaciones de K-RAS en c3ncer de colon. <i>Revista Espanola De Patologia</i> , <b>2012</b> , 45, 76-85	1.2	3
182	SEOM clinical guidelines for the treatment of pancreatic cancer. <i>Clinical and Translational Oncology</i> , <b>2011</b> , 13, 528-35	3.6	3
181	Development of new drug strategies in infrequent digestive tumors: esophageal, biliary tract, and anal cancers. <i>Current Opinion in Oncology</i> , <b>2009</b> , 21, 374-80	4.2	3

180	Monoclonal antibodies in solid tumours. <i>Current Clinical Pharmacology</i> , <b>2010</b> , 5, 160-5	2.5	3
179	A Phase I Dose Expansion Cohort Study of the Safety, Pharmacokinetics and Pharmacodynamics of SAR245409 (S09), An Orally Administered PI3K/mTOR Inhibitor, in Patients with Lymphoma. <i>Blood</i> , <b>2011</b> , 118, 1608-1608	2.2	3
178	Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAFV600 Mutations: A Cohort of the Histology-Independent VE-Basket Study. <i>Blood</i> , <b>2016</b> , 128, 480-480	2.2	3
177	PI3K pathway (PI3Kp) dysregulation and response to pan-PI3K/AKT/mTOR/dual PI3K-mTOR inhibitors (PI3Kpi) in metastatic breast cancer (MBC) patients (pts).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 509-509	2.2	3
176	The GAIN-C study (BP25438): Randomized phase II trial of RG7160 (GA201) plus FOLFIRI, compared to cetuximab plus FOLFIRI or FOLFIRI alone in second-line KRAS wild type (WT) or mutant metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, TPS3637-TPS3637	2.2	3
175	Phase Ib study evaluating safety and pharmacokinetics (PK) of the oral transforming growth factor-beta (TGF- $\beta$ ) receptor I kinase inhibitor LY2157299 monohydrate (LY) when combined with gemcitabine in patients with advanced cancer.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2563-2563	2.2	3
174	Prognostic factors (PFs) of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with metastatic pancreatic cancer (MPC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 4059-4059	2.2	3
173	Survival outcomes in patients (pts) with KRAS/NRAS (RAS) wild-type (WT) metastatic colorectal cancer (mCRC) and non-liver-limited disease (non-LLD): Data from the PRIME study.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3550-3550	2.2	3
172	REGARD: A phase 3, randomized, double-blind trial of ramucirumab (RAM) and best supportive care (BSC) versus placebo (PL) and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression (PD) on first-line platinum- and/or fluoropyrimidine-based combination therapy. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4057-4057	2.2	3
171	Analysis of metabolic response (MR) by positron emission tomography (PET) compared with tumor response by computed tomography (CT) from MPACT, a phase III trial comparing nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone for patients (pts) with metastatic adenocarcinoma of the pancreas.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 254-254	2.2	3
170	Candidate biomarker analyses in gastric or gastro-esophageal junction carcinoma: REGARD trial of single-agent ramucirumab (RAM) vs. placebo (PL).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4029-4029	2.2	3
169	MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, TPS3632-TPS3632	2.2	3
168	Validation of the prognostic impact of lymphocyte infiltration (LI) in patients (pts) with stage III colon cancer (CC) treated with adjuvant FOLFOX+/- cetuximab: A PETACC8 translational study.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 553-553	2.2	3
167	KEYNOTE-585: Phase 3 study of chemotherapy (chemo) + pembrolizumab (pembro) vs chemo + placebo as neoadjuvant/adjuvant treatment for patients (pts) with gastric or gastroesophageal junction (G/GEJ) cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS4136-TPS4136	2.2	3
166	Analysis of symptoms and functional HRQoL scales in TAGS, a phase III trial of trifluridine/tipiracil (FTD/TPI) in metastatic gastric cancer (mGC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4043-4043	2.2	3
165	A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, TPS3654-TPS3654	2.2	3
164	New players in cancer therapeutics: Focus on inhibitors of Mdm2-p53 protein-protein interaction. <i>Drugs of the Future</i> , <b>2012</b> , 37, 273	2.3	3
163	Drug development in the era of personalized oncology: from population-based trials to enrichment and prescreening strategies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2012</b> , 168-72	7.1	3



162	Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design. <i>Future Oncology</i> , <b>2021</b> , 17, 1977-1985	3.6	3
161	Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective. <i>Therapeutic Advances in Medical Oncology</i> , <b>2021</b> , 13, 17588359211042224	5.4	3
160	Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study. <i>ESMO Open</i> , <b>2021</b> , 6, 100200	6	3
159	The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology.. <i>Nature Cancer</i> , <b>2022</b> , 3, 251-261	15.4	3
158	The Effective Targeting of KRAS Elusiveness. <i>Cancer Cell</i> , <b>2020</b> , 38, 785-787	24.3	2
157	Design and Conduct of Early Clinical Studies of Immunotherapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT). <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 2461-2465	12.9	2
156	A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients. <i>British Journal of Cancer</i> , <b>2019</b> , 121, 378-383	8.7	2
155	TGR analysis in phase I clinical trials--letter. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 2495-6	12.9	2
154	Pharmacokinetic and pharmacodynamic evaluation of aflibercept for the treatment of colorectal cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2015</b> , 11, 995-1004	5.5	2
153	Unsupervised analyses reveal molecular subtypes associated to prognosis and response to therapy in colorectal cancer. <i>Colorectal Cancer</i> , <b>2014</b> , 3, 277-288	0.8	2
152	Circulating tumour cells in early breast cancer. <i>Lancet Oncology, The</i> , <b>2012</b> , 13, e370; author reply e370	21.7	2
151	Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2011</b> , 67, 75-82	3.5	2
150	Targeted therapies in thyroid cancer. <i>Targeted Oncology</i> , <b>2009</b> , 4, 275-85	5	2
149	Targeted therapies for patients with advanced colorectal cancer: focus on cetuximab. <i>Targeted Oncology</i> , <b>2006</b> , 1, 2-12	5	2
148	New approaches in systemic treatment of advanced colorectal cancer: the molecular targets era. <i>Expert Review of Anticancer Therapy</i> , <b>2007</b> , 7, 1027-41	3.5	2
147	Feasibility of CT scan-guided Tru-Cut serial liver biopsies to evaluate pharmacodynamic endpoints in patients with liver metastasis treated with experimental drugs. <i>Abdominal Imaging</i> , <b>2005</b> , 30, 65-8		2
146	Abstract 3363: Pharmacodynamic (PD) assessment of drug activity in tumor tissue from patients (pts) enrolled in a Phase I study of MEHD7945A (MEHD), a first-in-class HER3/EGFR dual action antibody, in pts with locally advanced or metastatic epithelial tumors. <b>2013</b> ,		2
145	Cetuximab combined with infusional 5-fluorouracil/folinic acid (5-FU/FA) and oxaliplatin in metastatic colorectal cancer (mCRC): A pooled analysis of COIN and OPUS study data.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3574-3574	2.2	2



144	Meta-analysis of anti-VEGF class adverse events from three double-blind (db), placebo (pbo)-controlled phase III trials with IV aflibercept (Afl).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3579-3579 <sup>2,2</sup>	2
143	Activity of the anti-IGF-1R antibody dalotuzumab (MK-0646) in KRAS-mutant colorectal cancer: Preclinical and clinical data.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3587-3587	2.2 2
142	A randomized, double-blind, phase (Ph) III study of the irinotecan-based chemotherapy FOLFIRI plus ramucirumab (RAM) or placebo (PL) in patients (pts) with metastatic colorectal carcinoma (mCRC) progressive during or following first-line therapy with bevacizumab (BEV), oxaliplatin (OXALI), and a fluoropyrimidine (FP) (RAISE) (NCT01183780).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, TPS3634-TPS3634	2.2 2
141	Genomic classifier (ColoPrint) to predict outcome and chemotherapy benefit in stage II and III colon cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3612-3612	2.2 2
140	CA19-9 decrease at 8 weeks as a predictor of overall survival (OS) in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients with metastatic pancreatic cancer (MPC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 4058-4058	2.2 2
139	ICE CREAM: Irinotecan cetuximab evaluation and the cetuximab response evaluation among patients with G13D mutation.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, TPS3649-TPS3649	2.2 2
138	Mutational analysis of biomarker samples from the CORRECT study: Correlating mutation status with clinical response to regorafenib.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 381-381	2.2 2
137	Analysis of overall survival and safety during the course of the phase III VELOUR trial comparing FOLFIRI and aflibercept or placebo in patients with mCRC that progressed on prior oxaliplatin treatment.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 451-451	2.2 2
136	On-treatment progression-free survival analysis of aflibercept-FOLFIRI treatment within 28 days of progression in metastatic colorectal cancer: Updated efficacy results from the VELOUR study.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 469-469	2.2 2
135	A phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2500-2500	2.2 2
134	First-in-human phase I Basket Study of Debio1347 (CH5183284), a novel FGFR inhibitor, in patients with FGFR genomically activated advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS2629-TPS2629	2.2 2
133	A randomized phase II study (B2151005) of the intravenous phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor PF-05212384 plus irinotecan versus cetuximab plus irinotecan in patients with wild-type KRAS metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS3610-TPS3610	2.2 2
132	RAS mutations in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab (C) in MRI-defined, high-risk rectal cancer (RC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 489-489	2.2 2
131	Analysis of DNA mismatch repair (MMR) and clinical outcome in stage III colon cancers from patients (pts) treated with adjuvant FOLFOX +/- cetuximab in the PETACC8 and NCCTG N0147 adjuvant trials.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3506-3506	2.2 2
130	Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, TPS3634-TPS3634	2.2 2
129	Multicohort phase II KEYNOTE-059 study of pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, TPS4135-TPS4135	2.2 2
128	Quality of life (QoL) during first-line treatment with FOLFOX4 with or without panitumumab (pmab) in RAS wild-type (WT) metastatic colorectal carcinoma (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 693-693	2.2 2
127	Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the CORRECT trial who had progression-free survival (PFS) longer than 4 months.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 710-710	2.2 2

126	LUME-Colon 1: A double-blind, randomized phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer (CRC) refractory to standard therapies.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, TPS794-TPS794	2.2	2
125	Matching degree between PI3K/AKT/mTOR (PAM) pathway mutations (mut) and therapy (ttx) as predictor of clinical benefit (ClinBen) in early trials.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2572-2572	2.2	2
124	Comprehensive profiling of biliary tract cancers (BTC) to reveal molecular heterogeneity with implications for matched targeted therapies (MTT).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4085-4085	2.2	2
123	A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors, followed by expansion cohorts in patients with FGFR genetic alterations.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS2602-TPS2602	2.2	2
122	TAS-102 versus placebo (PBO) in patients (pts) ≥5 years (y) with metastatic colorectal cancer (mCRC): An age-based analysis of the recourse trial.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 638-638	2.2	2
121	The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , <b>2021</b> , 22, 113	5.4	2
120	Subgroup analyses results of the PETACC8 phase III trial comparing adjuvant FOLFOX4 with or without cetuximab (CTX) in resected stage III colon cancer (CC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3525-3525	2.2	2
119	The Transcription Factor SLUG Uncouples Pancreatic Cancer Progression from the RAF-MEK1/2-ERK1/2 Pathway. <i>Cancer Research</i> , <b>2021</b> , 81, 3849-3861	10.1	2
118	Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival. <i>Npj Precision Oncology</i> , <b>2021</b> , 5, 33	9.8	2
117	Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. <i>Medicina Clínica</i> , <b>2021</b> , 156, 463.e1-463.e30	1	2
116	Molecular Subtyping Combined with Biological Pathway Analyses to Study Regorafenib Response in Clinically Relevant Mouse Models of Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 5979-5992	12.9	2
115	Landscape of , Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in -Mutated Cancers.. <i>JCO Precision Oncology</i> , <b>2022</b> , 6, e2100245	3.6	2
114	Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study.. <i>ESMO Open</i> , <b>2021</b> , 6, 100328	6	2
113	First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors. <i>Targeted Oncology</i> , <b>2016</b> , 11, 149-56	5	1
112	- and -Mutated Chemotherapy and Anti-EGFR-Refractory Colorectal Cancer: Should Clonality Guide Target Prioritization With Investigational Therapies?. <i>JCO Precision Oncology</i> , <b>2019</b> , 3, 1-3	3.6	1
111	ESMO-MCBS: setting the record straight. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, e192	21.7	1
110	Reply to the letter to the editor 'Re-aligning the ASCO and ESMO clinical benefit frameworks or modern cancer therapies'. <i>Annals of Oncology</i> , <b>2018</b> , 29, 774-775	10.3	1
109	RE: Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration. <i>Journal of the National Cancer Institute</i> , <b>2018</b> , 110, 1142-1143	9.7	1

108	Gastrointestinal cancer: Light and shade of intrahepatic arterial radiotherapy in mCRC. <i>Nature Reviews Clinical Oncology</i> , <b>2016</b> , 13, 467-8	19.4	1
107	Reply to the letter to the editor 'Can we trust burnout research?' by Bianchi et al. <i>Annals of Oncology</i> , <b>2017</b> , 28, 2625-2626	10.3	1
106	Treatment-related mortality with aflibercept in cancer patients. <i>European Journal of Clinical Pharmacology</i> , <b>2014</b> , 70, 1269-70	2.8	1
105	Cardiotoxicity <b>2013</b> , 483-530		1
104	Advances in targeted therapies for metastatic colorectal cancer. <i>Therapy: Open Access in Clinical Medicine</i> , <b>2009</b> , 6, 321-333		1
103	Biomarkers in colorectal cancer. <i>Clinical and Translational Oncology</i> , <b>2010</b> , 12, 261-70	3.6	1
102	Emerging strategies in the treatment of advanced esophageal, gastroesophageal junction, and gastric cancer: the introduction of targeted therapies. <i>Targeted Oncology</i> , <b>2006</b> , 1, 23-33	5	1
101	Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2005</b> , 28, 424	2.7	1
100	MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma—trial in progress.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, TPS371-TPS371	2.2	1
99	Phase I study of EMD 525797 (DI17E6), an antibody targeting $\alpha$ 5 $\beta$ 1 integrins, in combination with cetuximab and irinotecan, as a second-line treatment for patients with k-ras wild-type metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3539-3539	2.2	1
98	The role of TP, TS, and DPD as potential predictors of outcome following capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III colon cancer: Biomarker findings from study NO16968 (XELOXA).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3578-3578	2.2	1
97	International experts panel for the development of guidelines for the definition of time to event endpoints in clinical trials (DATECAN project): Results for pancreatic cancer.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4053-4053	2.2	1
96	POWER: An open-label, randomized phase III trial of cisplatin and 5-FU with or without panitumumab (P) for patients (pts) with nonresectable, advanced, or metastatic esophageal squamous cell cancer (ESCC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, TPS4158-TPS4158	2.2	1
95	Phase II trial of miniDOX (reduced-dose docetaxel/oxaliplatin/capecitabine) in suboptimal patients with advanced gastric cancer (AGC): TTD 08-02.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 87-87	2.2	1
94	Outcome evolution of matched molecular targeted agents (MTAs) in metastatic colorectal cancer (CRC) patients (pts): VHIO experience.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3602-3602	2.2	1
93	LUME-Colon 1: A double-blind, randomized phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer (CRC) refractory to standard therapies.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, TPS3625-TPS3625	2.2	1
92	Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, TPS789-TPS789	2.2	1
91	KEYNOTE-062: Phase 3 study of pembrolizumab alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS4138-TPS4138	2.2	1

90	TAGS, a randomized, double-blind, phase 3 study evaluating TAS-102 plus best supportive care vs placebo plus best supportive care in patients with metastatic gastric cancer refractory to standard treatments.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS4141-TPS4141	2.2	1
89	Prognostic impact of primary tumor site location in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 578-578	2.2	1
88	Survival determinants with matched targeted therapies in BRAF mutant metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 649-649	2.2	1
87	Baseline absolute neutrophil counts (ANC) and survival in second-line metastatic colorectal cancer (mCRC) patients (pts).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 713-713	2.2	1
86	PK/PD properties of BI 836880, a vascular endothelial growth factor (VEGF)/angiopoietin-2 (Ang-2)-blocking nanobody, in patients (pts) with advanced/metastatic solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2523-2523	2.2	1
85	Pharmacokinetic (PK) and exposure-response (ER) analysis of pertuzumab (P) in patients (pts) with HER2-positive metastatic gastroesophageal junction and gastric cancer (mGEJC/GC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2564-2564	2.2	1
84	A phase I, open-label dose-escalation trial of weekly (qw) BI 836880, a vascular endothelial growth factor (VEGF)/angiopoietin-2 (Ang-2)-blocking Nanobody, in patients (pts) with advanced/metastatic solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e24013-e24013	2.2	1
83	Concordance between independent and investigator assessment of disease-free survival (DFS) in the APACT trial.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4618-4618	2.2	1
82	A comprehensive overview of tumour deposits in colorectal cancer: Towards a next TNM classification.. <i>Cancer Treatment Reviews</i> , <b>2021</b> , 103, 102325	14.4	1
81	Phase III randomized sequential open-label study to evaluate the efficacy of FOLFOX + panitumumab followed by FOLFIRI + bevacizumab (Sequence 1) versus FOLFOX+ bevacizumab followed by FOLFIRI + panitumumab (Sequence 2) in untreated patients with wild-type RAS metastatic colorectal cancer (mCRC). The CO-SEQUENCE-1 trial.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 150-150	2.2	1
80	Patient and tumor characteristics as determinants of overall survival (OS) in BRAF V600 mutant (mt) metastatic colorectal cancer (mCRC) treated with doublet or triplet targeted therapy.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4112-4112	2.2	1
79	Aurora Kinases: A New Target for Anticancer Drug Development <b>2008</b> , 307-315		1
78	Molecular profiling in gynecologic cancer and matched targeted therapy: A step toward improving personalized medicine.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 5578-5578	2.2	1
77	Impact of early trials in molecularly-characterized patients (pts) with head and neck cancer (HNC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 6031-6031	2.2	1
76	Human pharmacokinetic (PK) characterization of the novel dual-action anti-HER3/EGFR antibody MEHD7945A (MEHD) in patients with refractory/recurrent epithelial tumors.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2567-2567	2.2	1
75	MONEO: A phase II study of avelumab (Av) plus FLOT in the peri-operative treatment for patients (pts) with resectable gastric or gastroesophageal junction cancer (GC).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS4155-TPS4155	2.2	1
74	Up-to-date role of aflibercept in the treatment of colorectal cancer. <i>Expert Opinion on Biological Therapy</i> , <b>2021</b> , 21, 1315-1324	5.4	1
73	Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH. <i>Medicina Clínica (English Edition)</i> , <b>2016</b> , 146, 511.e1-511.e22	0.3	1

72	Letter to the editor regarding the paper by A. Lozano-Blaquez et al. Differences in cancer drug assessment between Spain and the United Kingdom. <i>European Journal of Cancer</i> , <b>2016</b> , 67, 55-56	7.5	1
71	Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysis. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2021</b> , 87, 113-124	3.5	1
70	Reply to M. Mo et al. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 303	2.2	1
69	Biosimilars in oncology. <i>ESMO Open</i> , <b>2018</b> , 3, e000456	6	1
68	FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer. <i>Future Oncology</i> , <b>2021</b> , 17, 3151-3162	3.6	1
67	Single- and multiple-dose pharmacokinetics, potential for CYP3A inhibition, and food effect in patients with cancer and healthy subjects receiving ipatasertib. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2021</b> , 88, 921-930	3.5	1
66	High mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> ,	12.9	1
65	The Porto European Cancer Research Summit 2021. <i>Molecular Oncology</i> , <b>2021</b> , 15, 2507-2543	7.9	1
64	The Evolving Treatment Landscape in -Mutated Metastatic Colorectal Cancer.. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2022</b> , 42, 1-10	7.1	1
63	GDF15 Is an Eribulin Response Biomarker also Required for Survival of DTP Breast Cancer Cells. <i>Cancers</i> , <b>2022</b> , 14, 2562	6.6	1
62	Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer: an update. <i>Expert Review of Molecular Diagnostics</i> , <b>2020</b> , 20, 653-664	3.8	0
61	mTOR Inhibition Beyond Rapalogs <b>2016</b> , 251-275		0
60	Impact of molecular prescreening for genomically-guided trials in head and neck cancer (HNC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 6030-6030	2.2	0
59	Emerging biological drugs for the treatment of gastroesophageal adenocarcinoma. <i>Expert Opinion on Emerging Drugs</i> , <b>2021</b> , 1-16	3.7	0
58	Analysis of RSPO gene expression in solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e23235-e23235	2.2	0
57	Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , <b>2020</b> , 47, 5-18	2.7	0
56	Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study. <i>Gastric Cancer</i> , <b>2021</b> , 24, 970-977	7.6	0
55	Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. <i>Medicina Clínica (English Edition)</i> , <b>2021</b> , 156, 463.e1-463.e30	8.3	0



- 54 The Cancer Moonshot from a European perspective. *Lancet Oncology, The*, **2017**, 18, e626 21.7
- 53 Systemic Therapy for Patients with Colorectal Cancer: State of the Art **2015**, 109-132
- 52 Elucidating the molecular aspects of colorectal cancer and their clinical importance. *Colorectal Cancer*, **2015**, 4, 175-183 0.8
- 51 Reply to the letter to the editor 'ESMO-MCBS v1.1: statistical and patient relevant shortcomings' by Emprechtinger et al. *Annals of Oncology*, **2018**, 29, 1335-1338 10.3
- 50 Reply to the letter to the editor 'Toxicity adjustment in the ESMO-MCBS: a Gestalt approach?' by Del Paggio. *Annals of Oncology*, **2018**, 29, 521-522 10.3
- 49 Fibroblast Growth Factor Receptor Inhibitors: Enhancing Therapeutic Strategies for Solid Tumors **2019**, 101-121
- 48 Biomarker Discovery Strategies: DNA, RNA, and Protein **2013**, 401-416
- 47 Reply to the letter to the editor 'Addressing the quality of the ESMO-MCBS' by Del Paggio. *Annals of Oncology*, **2017**, 28, 2031-2032 10.3
- 46 Neuroendocrine tumors: The age of targeted therapies. *Endocrinología Y Nutrición (English Edition)*, **2012**, 59, 438-451
- 45 Similarities and differences between the adjuvant oxaliplatin-based trials MOSAIC and NSABP C-07. *Current Colorectal Cancer Reports*, **2009**, 5, 166-170 1
- 44 Optimal use of EGFR inhibitors: challenges, new drugs and future directions **2012**, 72-81
- 43 Medical Oncology Management of Hereditary Colorectal Cancer **2018**, 401-413
- 42 Association of postoperative carcinoembryonic antigen (CEA) levels with survival in stage III colon cancer (CC): Post hoc analysis of the MOSAIC and PETACC-8 studies.. *Journal of Clinical Oncology*, **2018**, 36, 3568-3568 2.2
- 41 The predictive role of plasma mutant allele fraction to antiangiogenic drugs in patients with mCRC: An expanded analysis of surrogate biomarkers of response to first-line treatment with bevacizumab.. *Journal of Clinical Oncology*, **2020**, 38, 3541-3541 2.2
- 40 Survival outcomes among older adults (OA) receiving second-line therapy for metastatic CRC (mCRC): 5,289 patients (pts) from the ARCAD Clinical Trials Program.. *Journal of Clinical Oncology*, **2020**, 38, 7009-7009 2.2
- 39 Coexisting KRAS and PIK3CA exon 20 mutations as a potential poor-prognosis factor in metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2014**, 32, 3591-3591 2.2
- 38 Survival outcomes in the PRIME study for patients (pts) with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC), by baseline Eastern Cooperative Oncology Group (ECOG) performance status (PS).. *Journal of Clinical Oncology*, **2014**, 32, 3557-3557 2.2
- 37 Incorporation of FGFR1 and FGFR2 amplification status determination in routine molecular prescreening for targeted therapies.. *Journal of Clinical Oncology*, **2014**, 32, 11105-11105 2.2

36	Prognostic value of KRAS exon 2 gene mutations in stage III colon cancer: Post hoc analyses of the PETACC8 trial.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3549-3549	2.2
35	Exploratory RAS analysis of the phase Ib/II 20060447 trial of rilotumumab (R) or ganitumab (G) plus panitumumab (pmab) versus pmab alone in patients (pts) with previously treated metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 694-694	2.2
34	Clinical and molecular characterization of refractory BRAF mutant metastatic colorectal carcinoma (mCRC): Vall d'Hebron Institute of Oncology phase I program cohort.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 587-587	2.2
33	Regional variation in physicians' awareness, understanding, and use of personalized medicine in the treatment of cancer and perception of patient (pt) education.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 574-574	2.2
32	A multicenter phase II basket clinical trial of lurbinectedin (PM01183) in selected advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, TPS2604-TPS2604	2.2
31	Measuring the impact of Next Generation Sequencing (NGS) technique implementation in metastatic colorectal cancer (mCRC) drug development program.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3598-3598	2.2
30	Comparison of three different molecular methods to detect mutations in KRAS, NRAS, BRAF and PIK3CA in metastatic colorectal cancer samples (mCRC): Interim analysis of a Spanish cohort.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e14613-e14613	2.2
29	Genomic landscape of anaplastic thyroid cancer.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 6033-6033	2.2
28	Early drug development in advanced gynecologic cancer based on genetic tumor profiling.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 5562-5562	2.2
27	Knocking on molecular alterations in advanced gastric cancer (AGC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4063-4063	2.2
26	Molecular prescreening (MP) to treat patients (pts) with advanced pancreatic cancer (PC) in early clinical trials.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 272-272	2.2
25	Clonality patterns of driver mutations (mut) to reveal spatial-temporal genomic heterogeneity in colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3509-3509	2.2
24	Comparison of three molecular methods to detect mutations in KRAS, NRAS, BRAF and PIK3CA in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3559-3559	2.2
23	Molecular markers to predict response to selective fibroblast growth factor receptor inhibitors (FGFRinh) in patients (pts) with FGFR-amplified (amp) or mutated (mut) tumors.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2581-2581	2.2
22	Drugs in clinical trials <b>2011</b> , 42-54	
21	Presentation and treatment of HER2-positive metastatic breast cancer patients already treated with adjuvant trastuzumab.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 619-619	2.2
20	Molecular profiling of patients (pts) with colorectal cancer (CRC) and matched targeted therapy (MTA) in phase I clinical trials.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3014-3014	2.2
19	Phase Ib study of CNTO 888 (anti-CCL 2) in combination with chemotherapies for treatment of patients with solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3059-3059	2.2

18	Prognostic significance of PI3K pathway (PI3Kp) dysregulation in metastatic breast cancer (MBC) patients (pts).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 566-566	2.2
17	Abstract A19: A qPCR assay, OncoScore Colon, predicts resistance to cetuximab in formalin-fixed, paraffin-embedded colorectal cancer tissue independent of KRAS status. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, A19-A19	12.9
16	Analysis of the intratumoral heterogeneity of PIK3CA mutant alleles in breast cancer (BC): Implications for the luminal (LUM) phenotype.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 10511-10511	2.2
15	Efficacy and safety of bevacizumab in metastatic colorectal cancer (mCRC): Pooled analysis from randomized controlled trials (RCTs).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3614-3614	2.2
14	Amplification of fibroblast growth factor receptor type 1 gene (FGFR1) in samples from 101 NSCLC patients (pts) with squamous cell carcinoma (SCC) histology.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 7041-7041	2.2
13	Biomarkers for Go/No Go Decisions <b>2013</b> , 417-436	
12	Long-term efficacy and pharmacodynamic parameter analysis in pretreated KRAS-mutant metastatic colorectal carcinoma (mCRC) patients treated with RG7160 (GA201), an antibody-dependent cellular cytotoxicity (ADCC)-enhanced monoclonal anti-EGFR antibody.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 379-379	2.2
11	Association of colorectal cancer intrinsic subtypes with prognosis, chemotherapy response, deficient mismatch repair, and epithelial to mesenchymal transition (EMT).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 333-333	2.2
10	Molecular characterization of nonpancreatic neuroendocrine neoplasms (NENS): First description of mutations in the tumor suppressor gene (TSG) SMARCB1 in NENS of colorectal origin using next-generation sequencing (NGS).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 4135-4135	2.2
9	Microarray gene expression study of the RESPECT trial for the identification of prognostic and predictive markers.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e14561-e14561	2.2
8	Molecular identification of basal-like breast cancer through genomic analyses across five cancer types.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1011-1011	2.2
7	Association of colorectal cancer intrinsic subtypes with prognosis, chemotherapy response, deficient mismatch repair, and epithelial to mesenchymal transition (EMT).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3530-3530	2.2
6	Relationship of RAS and TP53 predictive value for cetuximab (C) benefit: Results of the EXPERT-C trial.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 447-447	2.2
5	José "Pepe" Baselga, MD, PhD: In Memoriam (1959-2021). <i>Cancer Discovery</i> , <b>2021</b> , 11, 1614-1616	24.4
4	Educational needs in gastrointestinal cancer: a consensus position paper from the ESMO Gastrointestinal Cancer Faculty. <i>ESMO Open</i> , <b>2019</b> , 4, e000533	6
3	A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients. <i>Targeted Oncology</i> , <b>2018</b> , 13, 69-78	5
2	Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE study. <i>Current Medical Research and Opinion</i> , <b>2021</b> , 37, 1769-1778	2.5
1	Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials. <i>European Journal of Cancer</i> , <b>2021</b> , 155, 168-178	7.5

